Alnylam Pharmaceuticals
ALNY
$143.80
Share price
-1.55%
Change (1 day)
-29.78%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total assets
Total assets on the balance sheet as of December 2023 : $3.82 B
According to Alnylam Pharmaceuticals 's latest financial reports the company's total assets are $3.82 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Alnylam Pharmaceuticals - Total assets on balance sheet (from 2003 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-12-31 | $3.82 B | 7.99% |
| 2022-12-31 | $3.54 B | -2.66% |
| 2021-12-31 | $3.64 B | 6.93% |
| 2020-12-31 | $3.40 B | 42.25% |
| 2019-12-31 | $2.39 B | 52.09% |
| 2018-12-31 | $1.57 B | -21.05% |
| 2017-12-31 | $1.99 B | 57.96% |
| 2016-12-31 | $1.26 B | -8.92% |
| 2015-12-31 | $1.38 B | 28.43% |
| 2014-12-31 | $1.07 B | 156.72% |
| 2013-12-31 | $0.42 B | 46.26% |
| 2012-12-31 | $0.28 B | 1.99% |
| 2011-12-31 | $0.28 B | -28.31% |
| 2010-12-31 | $0.39 B | -18.31% |
| 2009-12-31 | $0.48 B | -13.21% |
| 2008-12-31 | $0.55 B | 12.33% |
| 2007-12-31 | $0.49 B | 105.74% |
| 2006-12-31 | $0.24 B | 144.04% |
| 2005-12-31 | $98.34 M | 48.77% |
| 2004-12-31 | $66.1 M | 87.89% |
| 2003-12-31 | $35.18 M | 118.38% |
| 2002-12-31 | $16.11 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $99.94 B | 2,509.61% | 🇨🇭 Switzerland |
 Sanofi SNY | $139.81 B | 3,550.66% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $33.08 B | 763.74% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $3.26 B | -14.76% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $37.74 M | -99.01% | 🇺🇸 USA |
 OPKO Health
OPK | $2.01 B | -47.47% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $43.47 B | 1,035.26% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.62 B | -83.65% | 🇺🇸 USA |